Enterprise Value

3.455B

Cash

1.883B

Avg Qtr Burn

-87.93M

Short % of Float

15.96%

Insider Ownership

1.49%

Institutional Own.

67.98%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

BLA

Acceptance for review

BLA

Acceptance for review

CTX110 (CD19) Details
CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies

Phase 2

Data readout

Phase 1/2

Update

Phase 1/2

Update

VCTX210 Details
Type 1 diabetes

Phase 1

Data readout

CTX130 (CD70) Details
Solid tumor/s, Blood cancer, Cancer

Phase 1

Update

CTX120 (BCMA) Details
Multiple myeloma, Blood cancer, Cancer

Failed

Discontinued